A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2014.977886

Related search